Evidence map›Paper›PMID 33200116›Full record

ArticleChemRxiv : the preprint server for chemistry2020

A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual Screening.

Christoph Gorgulla, Krishna M Padmanabha Das, Kendra E Leigh, Marco Cespugli, Patrick D Fischer, Zi-Fu Wang, Guilhem Tesseyre, Shreya Pandita, Alec Shnapir, Anthony Calderaio and 27 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemRxiv : the preprint server for chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Recent Advances in Clusteroluminescence.Topics in current chemistry (Cham) · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors.

Christoph GorgullaDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Krishna M Padmanabha DasDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Kendra E LeighMax-Planck-Institut für Biophysik, Frankfurt, Germany.
Marco CespugliInnophore GmbH, Graz, Austria.
Patrick D FischerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Zi-Fu WangDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Guilhem TesseyreGoogle, Mountain View, CA, USA.
Shreya PanditaGoogle, Mountain View, CA, USA.
Alec ShnapirGoogle, Mountain View, CA, USA.
Anthony CalderaioVirtualFlow Organization, https://virtual-flow.org/.
Minko GechevGoogle, Mountain View, CA, USA.
Alexander RoseMol Consortium, https://molstar.org.
Noam LewisGoogle, Mountain View, CA, USA.
Colin HutchesonGoogle, Mountain View, CA, USA.
Erez YaffeGoogle, Mountain View, CA, USA.
Roni LuxenburgGoogle, Mountain View, CA, USA.
Henry D HerceDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Vedat DurmazInnophore GmbH, Graz, Austria.
Thanos D HalazonetisDepartment of Molecular Biology, University of Geneva, Geneva, Switzerland.
Konstantin FackeldeyZuse Institute Berlin (ZIB), Berlin, Germany.
Justin J PattenDepartment of Microbiology, Boston University Medical School, Boston University, Boston, USA.
Alexander ChuprinaEnamine, Kyiv, Ukraine.
Igor DziubaUkrOrgSyntez Ltd., Kyiv, Ukraine.
Alla PlekhovaChemspace, Kyiv, Ukraine.
Yurii MorozChemspace, Kyiv, Ukraine.
Dmytro RadchenkoEnamine, Kyiv, Ukraine.
Olga TarkhanovaChemspace, Kyiv, Ukraine.
Irina YavnyukEnamine, Kyiv, Ukraine.
Christian GruberInnophore GmbH, Graz, Austria.
Ryan YustGoogle, Mountain View, CA, USA.
Dave PayneGoogle, Mountain View, CA, USA.
Anders M NäärDepartment of Nutritional Sciences & Toxicology, University of California Berkeley, USA.
Mark N NamchukDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Robert A DaveyDepartment of Microbiology, Boston University Medical School, Boston University, Boston, USA.
Gerhard WagnerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.
Jamie KinneyGoogle, Mountain View, CA, USA.
Haribabu ArthanariDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA.

Funding

NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteinsR01GM136859 · NIGMS · DANA-FARBER CANCER INST · PI ARTHANARI, HARIBABU · 2020 to 2024
$2.4M
NIGMS NIH HHS R01 GM136859
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), has spread rapidly across the globe, creating an unparalleled global health burden and spurring a deepening economic crisis. As of July 7th, 2020, almost seven months into the outbreak, there are no approved vaccines and few treatments available. Developing drugs that target multiple points in the viral life cycle could serve as a strategy to tackle the current as well as future coronavirus pandemics. Here we leverage the power of our recently developed

Indexed as

ACE2computational biologyCOVID-19 datadrug discoveryIn silicoMPronsp10nsp13nsp14-exonucleasensp16NSP16/NSP10nsp3 macrdomainnsp5nsp7nsp8nsp9nucleoproteinPLpro inhibitorsRdRPSARS-CoV -2SARS-CoV2 Small molecule inhibitorSpikeTMPRSS2virtual screening

Identifiers

PMID33200116
PMCPMC7668741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.